Aspen Pharmacare PE Ratio 2017-2024 | APNHY

Current and historical p/e ratio for Aspen Pharmacare (APNHY) from 2017 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Aspen Pharmacare PE ratio as of April 17, 2025 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Aspen Pharmacare PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2025-04-16 8.32 0.00
2024-06-30 12.53 0 0.00
2023-12-31 10.91 0 0.00
2023-06-30 9.35 0 0.00
2022-12-31 7.70 0 0.00
2022-06-30 7.97 0 0.00
2021-12-31 13.21 0 0.00
2021-06-30 10.55 0 0.00
2020-12-31 7.93 0 0.00
2020-06-30 7.68 0 0.00
2019-06-30 6.62 0 0.00
2018-12-31 8.71 0 0.00
2018-06-30 17.19 0 0.00
2017-12-31 20.45 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.000B $2.392B
Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.010B 6.96
Dr Reddy's Laboratories (RDY) India $11.261B 21.48
BridgeBio Pharma (BBIO) United States $6.894B 0.00
Bausch Health Cos (BHC) Canada $2.638B 1.91
Supernus Pharmaceuticals (SUPN) United States $1.805B 24.57
Amphastar Pharmaceuticals (AMPH) United States $1.553B 9.33
Taysha Gene Therapies (TSHA) United States $0.338B 23.57
Personalis (PSNL) United States $0.323B 0.00
Assembly Biosciences (ASMB) United States $0.080B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00